significantly increased total visceral adipose weight compared
with LF mice in both Expts. 1 (Fig. 1B) and 2 (Fig. 1D) For Expt.
1, EGCG treatment reduced the weight of the mesenteric adipose
depot (19% decrease) and retroperitoneal adipose depot (21%
decrease) in HF mice (Fig. 1B). In Expt. 2, EGCG treatment
reduced total visceral adipose tissue weight by 37% in HF mice
(P , 0.05; Fig. 1D). This was attributable to weight decreases in
the mesenteric (48% decrease), epididymal (28% decrease), and
retroperitoneal (34% decrease) depots (P , 0.05 for all depots;
Fig. 1D).